ARIAD
Pharmaceuticals, Inc. ARIA today announced results of
evaluation of the cardiovascular risk profile of Philadelphia-positive
(Ph+) leukemia patients treated with Iclusig® (ponatinib) in
the pivotal PACE trial. Serious arterial thrombotic (AT) events can be a
complication of BCR-ABL tyrosine kinase inhibitor (TKI) therapy in Ph+
leukemias. In the single-arm, PACE trial, serious AT events, including
cardiovascular, cerebrovascular and peripheral vascular events, occurred
in 34 of 449 patients (8%). This analysis showed that patients who
experienced serious ATs while on study more commonly had a history of
pre-existing cardiac disease and a higher prevalence of baseline
cardiovascular risk factors prior to enrollment than in those patients
who did not experience these events.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in